Login
$ACET
$2.75 -$0.03 (1.08%) Live

Company Executives

Officer Age In this role Source
Chen Schor Also a director
Chief Executive Officer and President
53 Not stated
Nick Harvey
Chief Financial Officer
65 Not stated
Blake Aftab
Chief Scientific Officer
44 Since 2021
5 years
Donald Healey
Chief Technology Officer
64 Since 2020
6 years
Julia Maltzman
Chief Medical Officer
58 Since 2025
1 year
Lloyd Klickstein, M.D., Ph.D. Also a director
Chief Medical Officer
Title from the Form 4 dated Aug 5, 2026
69 Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 29, 2026 · updated by the 8-K of Nov 13, 2026

Directors
5
serving now
Independent
4 of 5
stated in the proxy
Average tenure
4.6 years
from year joined
Director Age On board Independent Committees Other public boards 2025 pay Source
Jeffrey Chodakewitz, M.D.
70 2020
6 years
Independent
Compensation Committee · Chair
Praxis Precision Medicines, Inc. (Nasdaq: PRAX), Schrodinger, Inc. (Nasdaq: SDGR) $68,876
Steve Dubin, J.D.
72 2020
6 years
Independent None stated None stated $82,106
Chen Schor, MBA
53 2020
6 years
Not independent None stated Karyopharm Therapeutics Inc. (Nasdaq: KPTI) Not stated
Katie Peng, MBA
55 2023
3 years
Independent None stated Scholar Rock Holding Corporation (Nasdaq: SRRK) Not stated
Lloyd Klickstein, M.D., Ph.D.
69 2024
2 years
Independent
Nominating and Corporate Governance Committee
None stated $64,345
  • An 8-K filed Nov 13, 2026 says Michael Grissinger changed role; they could not be matched to a director above.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 29, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support